| Nov 1 |
Cellectar Biosciences regains compliance with Nasdaq
|
| Nov 1 |
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
|
| Aug 30 |
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131
|
| Aug 26 |
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
|
| Aug 23 |
Cellectar receives delinquency notification letter from Nasdaq, co to restate financial statements
|
| Aug 23 |
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
|
| Aug 13 |
Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
Cellectar Biosciences reports Q2 results
|
| Aug 13 |
Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update
|
| Aug 12 |
Cellectar Biosciences Q2 2024 Earnings Preview
|
